{
    "2020-04-08": [
        [
            {
                "time": "2018-06-07",
                "original_text": "U.S. FDA Approves BRAFTOVIÂ® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy",
                "features": {
                    "keywords": [
                        "FDA Approval",
                        "BRAFTOVI",
                        "Encorafenib",
                        "Cetuximab",
                        "BRAFV600E-Mutant",
                        "Metastatic Colorectal Cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-07",
                "original_text": "Pfizer Stock Rises 3%",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Stock Rises",
                        "3%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}